These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 33909086)

  • 1.
    Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
    Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
    BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
    Mikhaeel NG; Cunningham D; Counsell N; McMillan A; Radford JA; Ardeshna KM; Lawrie A; Smith P; Clifton-Hadley L; O'Doherty MJ; Barrington SF
    Br J Haematol; 2021 Feb; 192(3):504-513. PubMed ID: 32621535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of PET/CT evaluation with Deauville score on the recurrence and survival in diffuse large B-cell lymphoma: a multi-institutional study of KROG 17-02.
    Lee JW; Oh D; Eom KY; Kim JH; Kim WC; Chung MJ; Lee JH
    Clin Exp Metastasis; 2020 Feb; 37(1):125-131. PubMed ID: 31555945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
    Lombion N; Robin P; Tempescul A; LE Roux PY; Schick U; Guillerm G; Ianotto JC; Berthou C; Salaün PY; Abgral R
    Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):402-409. PubMed ID: 35133099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
    Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
    Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic tumour area: a novel prognostic indicator based on
    Cui S; Xin W; Wang F; Shao X; Shao X; Niu R; Zhang F; Shi Y; Liu B; Gu W; Wang Y
    BMC Cancer; 2024 Jul; 24(1):895. PubMed ID: 39054508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
    Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
    Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.
    Kim J; Song YS; Lee JS; Lee WW; Kim SE
    Leuk Lymphoma; 2018 Feb; 59(2):340-347. PubMed ID: 28629257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma.
    El-Azony A; Basha MAA; Almalki YE; Abdelmaksoud B; Hefzi N; Alnagar AA; Mahdey S; Ali IM; Nasr I; Abdalla AAEM; Yousef HY; Zaitoun MMA; Elsayed SB; Nada MG; Amin MI; Hassan RM; Ali SA; Dawoud TM; Aly SA; Algazzar YH; Abdelhamed H
    Eur Radiol; 2024 Apr; 34(4):2500-2511. PubMed ID: 37812294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.
    Pregno P; Chiappella A; Bellò M; Botto B; Ferrero S; Franceschetti S; Giunta F; Ladetto M; Limerutti G; Menga M; Nicolosi M; Priolo G; Puccini B; Rigacci L; Salvi F; Vaggelli L; Passera R; Bisi G; Vitolo U
    Blood; 2012 Mar; 119(9):2066-73. PubMed ID: 22234681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
    Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
    Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
    Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
    Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUV
    Fan Y; Zhang Y; Yang Z; Ying Z; Zhou N; Liu C; Song Y; Zhu J; Wang X
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28535082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.